The purpose of this study is to look at how feasible it is to incorporate a state-of-the-art smoking cessation treatment program into community substance abuse treatment programs and its impact on substance abuse and cigarette smoking.

Condition	Treatment or Intervention	Phase
Tobacco Use Disorder	Drug: nicotine transdermal system	Phase III

Further Study Details: 

Expected Total Enrollment:  585

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Patient is alcohol or drug dependent, in Outpatient Drug-Free or Opiate Substitute program and is interested in quitting smoking

Exclusion Criteria:

• Patient is psychotic
• Use of smokeless tobacco
• Use of other smoking cessasation product
• Pregnancy
• Patient has hyper-tension, heart problems, or skin condition

California
      Matrix Institute on Addictions, Los Angeles,  California,  90016,  United States
      Tarzana Treatment Center, Tarzana,  California,  91356,  United States
Florida
      Center for Drug Free Living, Orlando,  Florida,  32805,  United States
      SPECTRUM, Miami,  Florida,  33156,  United States
Michigan
      Chelsea Arbor Addictions Treatment Center, Ann Arbor,  Michigan,  48103,  United States
      Psychiatry and Behavioral Medicine Professionals I, Detroit,  Michigan,  48207,  United States
New York
      Mount Sinai Medical Center, New York,  New York,  10029,  United States
      Narco Freedom (Bridge Plaza), Long Island City,  New York,  11101,  United States
      St. Luke's Roosevelt Hospital Center, New York,  New York,  10019,  United States
      St. Luke's Roosevelt Hospital Center, Womens, New York,  New York,  10025,  United States
North Carolina
      Coastal Horizons Center, Inc., Wilmington,  North Carolina,  28412,  United States
      Piedmont Behavioral Healthcare, Concord,  North Carolina,  28001,  United States
South Carolina
      Behavioral Health Services of Pickens County, Pickens,  South Carolina,  29671,  United States

Study chairs or principal investigators

Malcolm Reid, Ph.D.,  Principal Investigator,  New York University School of Medicine   

Study ID Numbers:  NIDA-CTN-0009-1
Record last reviewed:  January 2005
Last Updated:  February 16, 2005
Record first received:  August 12, 2003
ClinicalTrials.gov Identifier:  NCT00067158
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08